Skip to content

Mirum Pharmaceuticals, Inc. MIRM Other intangible assets—net

Other intangible assets—net at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$18.24B-18.9%
Gilead Sciences logo
Gilead SciencesGILD
LQD
Liquidia CorporationLQDA
Alkermes logo
AlkermesALKS
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Merck & Co. logo
Merck & Co.MRK

Other financials

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%
Free cash flow-$229.4M-11,360%

Valuation

See full
Market cap$6.53B+152%
Enterprise value$6.28B+162%
P/S11.5×+4.6×

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp
FCF margin-30.3%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.1×-1.1×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s other intangible assets—net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s other intangible assets—net?
Mirum Pharmaceuticals, Inc. (MIRM) reported other intangible assets—net of $254.15M in Q1 2026.
How has Mirum Pharmaceuticals, Inc.'s other intangible assets—net changed year-over-year?
Mirum Pharmaceuticals, Inc.'s other intangible assets—net increased by 4.2% year-over-year, from $243.85M to $254.15M.
What does other intangible assets—net mean?
This represents the net book value of identifiable non-physical assets such as patents, intellectual property, software licenses, and trademarks, excluding goodwill. These assets are vital for companies relying on proprietary technology and R&D. It captures the value of the company's competitive moat derived from its intellectual property portfolio.